Literature DB >> 31226725

Contributions of Fibroblasts, Extracellular Matrix, Stiffness, and Mechanosensing to Hepatocarcinogenesis.

Aveline Filliol1, Robert F Schwabe1,2.   

Abstract

Hepatocellular carcinoma (HCC) is the third leading cause of cancer mortality worldwide. A unique feature of liver cancer is its close association with liver fibrosis. About 90% of HCCs develop in advanced liver fibrosis or cirrhosis, suggesting an important role for the fibrotic microenvironment in driving HCC development. Here, the authors will discuss functional contributions of liver fibrosis to the development of HCC, focusing on mechanisms through which fibrosis may promote HCC development such as hepatic stellate cell-derived extracellular matrix, growth factors, and cytokines, stiffness-induced signaling pathways, and immunosuppression. Better understanding of these factors in HCC development and progression may provide the basis for novel stromal-based therapies for tumor prevention or therapy. Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31226725     DOI: 10.1055/s-0039-1685539

Source DB:  PubMed          Journal:  Semin Liver Dis        ISSN: 0272-8087            Impact factor:   6.115


  11 in total

1.  Screening potential prognostic biomarkers for portal vein emboli in patients with hepatocellular carcinoma.

Authors:  Weijie Zhou; Da Lang Fang; Yongfei He
Journal:  J Gastrointest Oncol       Date:  2021-08

2.  Biomechanical assessment of chronic liver injury using quantitative micro-elastography.

Authors:  Alireza Mowla; Rose Belford; Julia Köhn-Gaone; Nathan Main; Janina E E Tirnitz-Parker; George C Yeoh; Brendan F Kennedy
Journal:  Biomed Opt Express       Date:  2022-09-01       Impact factor: 3.562

Review 3.  Mechanisms of Fibrosis Development in Nonalcoholic Steatohepatitis.

Authors:  Robert F Schwabe; Ira Tabas; Utpal B Pajvani
Journal:  Gastroenterology       Date:  2020-02-08       Impact factor: 22.682

Review 4.  Liver specific, systemic and genetic contributors to alcohol-related liver disease progression.

Authors:  Bernd Schnabl; Gavin E Arteel; Felix Stickel; Jan Hengstler; Nachiket Vartak; Ahmed Ghallab; Steven Dooley; Yujia Li; Robert F Schwabe
Journal:  Z Gastroenterol       Date:  2022-01-18       Impact factor: 1.769

5.  Dual Pharmacological Targeting of HDACs and PDE5 Inhibits Liver Disease Progression in a Mouse Model of Biliary Inflammation and Fibrosis.

Authors:  Alex Claveria-Cabello; Leticia Colyn; Iker Uriarte; Maria Ujue Latasa; Maria Arechederra; Jose M Herranz; Laura Alvarez; Jesus M Urman; Maria L Martinez-Chantar; Jesus M Banales; Bruno Sangro; Krista Rombouts; Julen Oyarzabal; Jose J G Marin; Carmen Berasain; Matias A Avila; Maite G Fernandez-Barrena
Journal:  Cancers (Basel)       Date:  2020-12-13       Impact factor: 6.639

Review 6.  Modulating the Crosstalk between the Tumor and Its Microenvironment Using RNA Interference: A Treatment Strategy for Hepatocellular Carcinoma.

Authors:  Mariam Mroweh; Thomas Decaens; Patrice N Marche; Zuzana Macek Jilkova; Flora Clément
Journal:  Int J Mol Sci       Date:  2020-07-24       Impact factor: 5.923

7.  Matrix stiffness promotes glioma cell stemness by activating BCL9L/Wnt/β-catenin signaling.

Authors:  Bei Tao; Yi Song; Yao Wu; Xiaobo Yang; Tangming Peng; Lilei Peng; Kaiguo Xia; Xiangguo Xia; Ligang Chen; Chuanhong Zhong
Journal:  Aging (Albany NY)       Date:  2021-02-01       Impact factor: 5.682

8.  Sulfatase 2-Induced Cancer-Associated Fibroblasts Promote Hepatocellular Carcinoma Progression via Inhibition of Apoptosis and Induction of Epithelial-to-Mesenchymal Transition.

Authors:  Cong Wang; Chuzhi Shang; Xiaohong Gai; Tao Song; Shaoshan Han; Qingguang Liu; Xin Zheng
Journal:  Front Cell Dev Biol       Date:  2021-04-06

9.  An Integrated Fibrosis Signature for Predicting Survival and Immunotherapy Efficacy of Patients With Hepatocellular Carcinoma.

Authors:  Long Liu; Zaoqu Liu; Lingfang Meng; Lifeng Li; Jie Gao; Shizhe Yu; Bowen Hu; Han Yang; Wenzhi Guo; Shuijun Zhang
Journal:  Front Mol Biosci       Date:  2021-12-14

10.  TREM-2 defends the liver against hepatocellular carcinoma through multifactorial protective mechanisms.

Authors:  Aitor Esparza-Baquer; Ibone Labiano; Omar Sharif; Aloña Agirre-Lizaso; Fiona Oakley; Pedro M Rodrigues; Ekaterina Zhuravleva; Colm J O'Rourke; Elizabeth Hijona; Raul Jimenez-Agüero; Ioana Riaño; Ana Landa; Adelaida La Casta; Marco Y W Zaki; Patricia Munoz-Garrido; Mikel Azkargorta; Felix Elortza; Andrea Vogel; Gernot Schabbauer; Patricia Aspichueta; Jesper B Andersen; Sylvia Knapp; Derek A Mann; Luis Bujanda; Jesus Maria Banales; Maria Jesus Perugorria
Journal:  Gut       Date:  2020-09-09       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.